CIBC Private Wealth Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $34.6K | Buy |
183
+34
| +23% | +$6.53K | ﹤0.01% | 1942 |
|
|
2025
Q3 | $26.4K | Buy |
149
+69
| +86% | +$10.3K | ﹤0.01% | 2052 |
|
|
2025
Q2 | $9.09K | Sell |
80
-123
| -61% | -$13.1K | ﹤0.01% | 2286 |
|
|
2025
Q1 | $19.6K | Buy |
203
+43
| +27% | +$4.86K | ﹤0.01% | 2001 |
|
|
2024
Q4 | $17.7K | Hold |
160
| – | – | ﹤0.01% | 2108 |
|
|
2024
Q3 | $16K | Hold |
160
| – | – | ﹤0.01% | 2254 |
|
|
2024
Q2 | $13.9K | Hold |
160
| – | – | ﹤0.01% | 2173 |
|
|
2024
Q1 | $11.8K | Buy |
+160
| New | +$11.8K | ﹤0.01% | 2217 |
|
|
2022
Q4 | – | Sell |
-19,302
| Closed | -$1.04M | – | 904 |
|
|
2022
Q3 | $1.04M | Hold |
19,302
| – | – | ﹤0.01% | 584 |
|
|
2022
Q2 | $1.07M | Hold |
19,302
| – | – | ﹤0.01% | 587 |
|
|
2022
Q1 | $1.35M | Sell |
19,302
-27
| -0.1% | -$1.96K | ﹤0.01% | 590 |
|
|
2021
Q4 | $1.86M | Sell |
19,329
-186
| -1% | -$17.2K | ﹤0.01% | 534 |
|
|
2021
Q3 | $1.7M | Sell |
19,515
-3,092
| -14% | -$239K | ﹤0.01% | 532 |
|
|
2021
Q2 | $1.85M | Sell |
22,607
-48
| -0.2% | -$3.99K | ﹤0.01% | 544 |
|
|
2021
Q1 | $2.15M | Buy |
22,655
+1,545
| +7% | +$146K | 0.01% | 529 |
|
|
2020
Q4 | $1.31M | Sell |
21,110
-2,917
| -12% | -$166K | ﹤0.01% | 579 |
|
|
2020
Q3 | $1.43M | Buy |
24,027
+35
| +0.1% | +$2.39K | ﹤0.01% | 499 |
|
|
2020
Q2 | $1.67M | Sell |
23,992
-7,327
| -23% | -$464K | 0.01% | 399 |
|
|
2020
Q1 | $1.42M | Sell |
31,319
-4,524
| -13% | -$256K | 0.01% | 463 |
|
|
2019
Q4 | $2.33M | Sell |
35,843
-75,009
| -68% | -$5.01M | 0.01% | 449 |
|
|
2019
Q3 | $6.88M | Sell |
110,852
-5,648
| -5% | -$355K | 0.02% | 318 |
|
|
2019
Q2 | $8.29M | Sell |
116,500
-6,505
| -5% | -$479K | 0.03% | 314 |
|
|
2019
Q1 | $9.65M | Buy |
123,005
+12,238
| +11% | +$927K | 0.04% | 280 |
|
|
2018
Q4 | $9.38M | Buy |
110,767
+14,143
| +15% | +$1.51M | 0.04% | 267 |
|
|
2018
Q3 | $16.5M | Sell |
96,624
-15,669
| -14% | -$2.36M | 0.06% | 232 |
|
|
2018
Q2 | $14.5M | Sell |
112,293
-124,927
| -53% | -$13.9M | 0.06% | 241 |
|
|
2018
Q1 | $24.4M | Buy |
237,220
+1,848
| +0.8% | +$183K | 0.11% | 184 |
|
|
2017
Q4 | $20.1M | Buy |
235,372
+4,798
| +2% | +$416K | 0.09% | 204 |
|
|
2017
Q3 | $19.6M | Buy |
230,574
+4,072
| +2% | +$322K | 0.09% | 195 |
|
|
2017
Q2 | $17.2M | Sell |
226,502
-1,754
| -0.8% | -$123K | 0.11% | 154 |
|
|
2017
Q1 | $15.1M | Sell |
228,256
-1,888
| -0.8% | -$124K | 0.09% | 159 |
|
|
2016
Q4 | $14.6M | Buy |
230,144
+396
| +0.2% | +$25K | 0.1% | 162 |
|
|
2016
Q3 | $14.6M | Sell |
229,748
-39,372
| -15% | -$2.89M | 0.1% | 158 |
|
|
2016
Q2 | $20M | Buy |
+269,120
| New | +$20M | 0.15% | 131 |
|
Other funds holding LGND
NAMI
CC
SIMG
CIBC Private Wealth Group's LGND Position: Q4 2025 in Review
CIBC Private Wealth Group increased its Ligand Pharmaceuticals (LGND) stake by 23% in Q4 2025, buying an estimated $6.53K and bringing the position to 183 shares worth $34.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1942.
CIBC Private Wealth Group first reported a position in LGND in Q2 2016 and has held it in 34 quarters since. The position peaked at $24.4M in Q1 2018. 349 funds tracked by Wall St. Rank hold LGND as of Q4 2025.
- CIBC Private Wealth Group held 183 shares of Ligand Pharmaceuticals worth $34.6K as of Q4 2025.
- CIBC Private Wealth Group bought 34 Ligand Pharmaceuticals shares in Q4 2025, an estimated $6.53K.
- Ligand Pharmaceuticals made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #1942 holding.
- CIBC Private Wealth Group first reported a position in Ligand Pharmaceuticals in Q2 2016 and has held it in 34 quarters since.
- CIBC Private Wealth Group's Ligand Pharmaceuticals position peaked at $24.4M in Q1 2018.
- 349 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.
Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.